N,5-dimethylpyrazine-2-carboxamide | 7132-15-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: N,5-dimethylpyrazine-2-carboxamide
• CAS: 7132-15-2
• 化学式: C₇H₉N₃O
• mdl: MFCD07369006
• 分子量: 151.17
• InChiKey: OVKAHOFMCGWRAN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  54.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N,5-dimethylpyrazine-2-carboxamide 以58%的产率得到
  参考文献：
  名称：

  ANTEUNIS, M. J. O.;HOSTEN, N. G. C.;BORREMANS, F. A. M.;TAVERNIER, D. K., BULL. SOC. CHIM. BELG., 1983, 92, N 11-12, 999-1010

  摘要：

  DOI：
• 作为产物：
  描述：

  5-甲基吡嗪-2-羧酸 、 6-甲基吡嗪-2-羧酸 、 甲胺 、 氯化亚砜 以16%的产率得到
  参考文献：
  名称：

  ANTEUNIS, M. J. O.;HOSTEN, N. G. C.;BORREMANS, F. A. M.;TAVERNIER, D. K., BULL. SOC. CHIM. BELG., 1983, 92, N 11-12, 999-1010

  摘要：

  DOI：

文献信息

• [EN] 5,6-DIHYDRO-2H-[1,4]OXAZIN-3-YL-AMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)<br/>[FR] DÉRIVÉS DE 5,6-DIHYDRO-2H-[1,4]OXAZIN-3-YLAMINE UTILES COMME INHIBITEURS DE BÊTA-SÉCRÉTASE (BACE)
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2011154431A1

  公开（公告）日：2011-12-15

  The present invention relates to novel 5,6-dihydro-2H-[1,4]oxazin-3-ylamine derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease and dementia associated with beta- amyloid.

  本发明涉及新型5,6-二氢-2H-[1,4]噁唑啉-3-胺衍生物，作为β-分泌酶抑制剂，也被称为β-位点淀粉样蛋白裂解酶、BACE、BACE1、Asp2或memapsin2。该发明还涉及包含这些化合物的药物组合物，用于制备这些化合物和组合物的方法，以及用于预防和治疗涉及β-分泌酶的疾病的这些化合物和组合物的用途，如阿尔茨海默病（AD）、轻度认知障碍、老年痴呆、带有Lewy小体的痴呆、唐氏综合征、与中风相关的痴呆、与帕金森病相关的痴呆以及与β-淀粉样蛋白相关的痴呆。
• SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE
  申请人：Emelen Van Kristof

  公开号：US20070142393A1

  公开（公告）日：2007-06-21

  This invention comprises the novel compounds of formula (I) wherein n, m, t, R 1 , R 2 , R 3 , R 4 , L, Q, X, Y, Z and have defined meanings, having histone deacetylase inhibiting enzymatic activity; their preparation, compositions containing them and their use as a medicine.

  这项发明涉及公式（I）中的新化合物，其中n，m，t，R1，R2，R3，R4，L，Q，X，Y，Z和具有定义的含义，具有组织脱乙酰化酶抑制酶活性；它们的制备，包含它们的组合物以及它们作为药物的用途。
• Sulfonyl-Derivatives as Novel Inhibitors or Histone Deacetylase
  申请人：Van Emelen Kristof

  公开号：US20080108601A1

  公开（公告）日：2008-05-08

  This invention comprises the novel compounds of formula (I) wherein n, m, t, R 1 , R 2 , R 3 , R 4 , L, Q, X, Y, Z and have defined meanings, having histone deacetylase inhibiting enzymatic activity; their preparation, compositions containing them and their use as a medicine.

  这项发明包括具有组成式（I）的新化合物，其中n，m，t，R1，R2，R3，R4，L，Q，X，Y，Z和具有定义的含义，具有组蛋白去乙酰化酶抑制酶活性；它们的制备，含有它们的组合物以及它们作为药物的用途。
• Compositions For Treating Flushing And Lipid-Associated Disorders Comprising Niacin Receptor Partial Agonists
  申请人：Behan Dominic P.

  公开号：US20080139628A1

  公开（公告）日：2008-06-12

  The invention provides a method of reducing flushing induced by niacin or a niacin analog in a subject, comprising administering to said subject an effective flush reducing amount of a niacin receptor partial agonist. In addition, the invention provides a method of reducing flushing induced by niacin or a niacin analog in a subject, comprising administering to said subject an effective flush reducing amount of a niacin receptor partial agonist and an effective lipid altering amount of niacin or a niacin analog. The invention further provides a method of reducing flushing induced by niacin or a niacin analog in a subject, comprising administering to said subject an effective flush reducing amount of a niacin receptor partial agonist and subsequently administering to said subject an effective lipid altering amount of niacin or a niacin analog.

  本发明提供了一种减少烟酸或烟酸类似物引起的面红的方法，包括向该受体中注射有效减少面红量的烟酸受体部分激动剂。此外，本发明还提供了一种减少烟酸或烟酸类似物引起的面红的方法，包括向该受体中注射有效减少面红量的烟酸受体部分激动剂和有效改变脂质含量的烟酸或烟酸类似物。本发明进一步提供了一种减少烟酸或烟酸类似物引起的面红的方法，包括向该受体中注射有效减少面红量的烟酸受体部分激动剂，然后向该受体中注射有效改变脂质含量的烟酸或烟酸类似物。
• Sulfonyl-Derivatives as Novel or Histone Deacetylase
  申请人：Van Emelen Kristof

  公开号：US20100240639A1

  公开（公告）日：2010-09-23

  This invention comprises the novel compounds of formula (I) wherein n, m, t, R 1 , R 2 , R 3 , R 4 , L, Q, X, Y, Z and have defined meanings, having histone deacetylase inhibiting enzymatic activity; their preparation, compositions containing them and their use as a medicine.

  这项发明涉及公式(I)的新型化合物，其中n、m、t、R1、R2、R3、R4、L、Q、X、Y、Z和具有定义的含义，具有组蛋白去乙酰化酶抑制酶活性；它们的制备，含有它们的组合物以及它们作为药物的用途。